Evidence map›Paper›PMID 31551669›Full record

ReviewFrontiers in neuroscience2019

Neuronal Sigma-1 Receptors: Signaling Functions and Protective Roles in Neurodegenerative Diseases.

Daniel A Ryskamp, Svetlana Korban, Vladimir Zhemkov, Nina Kraskovskaya, Ilya Bezprozvanny

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in neuroscience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 115 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
115citing papers in PubMed, 1 pooled it
8.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

115 citing papers in PubMed, 1 synthesis or guideline pooled it, 201 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. The SigmaPharmacological reports : PR · 2026
    Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

55 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Daniel A RyskampDepartment of Physiology, UT Southwestern Medical Center at Dallas, Dallas, TX, United States.
Svetlana KorbanLaboratory of Molecular Neurodegeneration, Peter the Great St. Petersburg State Polytechnic University, Saint Petersburg, Russia.
Vladimir ZhemkovDepartment of Physiology, UT Southwestern Medical Center at Dallas, Dallas, TX, United States.
Nina KraskovskayaLaboratory of Molecular Neurodegeneration, Peter the Great St. Petersburg State Polytechnic University, Saint Petersburg, Russia.
Ilya BezprozvannyDepartment of Physiology, UT Southwestern Medical Center at Dallas, Dallas, TX, United States.
Peter the Great St. Petersburg Polytechnic University · RUSouthwestern Medical CenterSouthwestern Medical Center · USThe University of Texas Southwestern Medical Center · US

Funding

Deranged calcium signaling and polyglutamine expansion disordersR01NS056224 · NINDS · UT SOUTHWESTERN MEDICAL CENTER · PI BEZPROZVANNY, ILYA B · 2008 to 2020
$3.5M
Calcium signaling and synaptic maintenance in Alzheimers diseaseRF1AG055577 · NIA · UT SOUTHWESTERN MEDICAL CENTER · PI BEZPROZVANNY, ILYA B, KAVALALI, EGE T · 2017 to 2017
$3.0M
Synaptic calcium dysregulation in Huntington's diseaseF32NS093786 · NINDS · UT SOUTHWESTERN MEDICAL CENTER · PI RYSKAMP, DANIEL AARON · 2015 to 2017
$174k
NIA NIH HHS RF1 AG055577NINDS NIH HHS F32 NS093786NINDS NIH HHS R01 NS056224
6 · The paper itself

Abstract

Sigma-1 receptor (S1R) is a multi-functional, ligand-operated protein situated in endoplasmic reticulum (ER) membranes and changes in its function and/or expression have been associated with various neurological disorders including amyotrophic lateral sclerosis/frontotemporal dementia, Alzheimer's (AD) and Huntington's diseases (HD). S1R agonists are broadly neuroprotective and this is achieved through a diversity of S1R-mediated signaling functions that are generally pro-survival and anti-apoptotic; yet, relatively little is known regarding the exact mechanisms of receptor functioning at the molecular level. This review summarizes therapeutically relevant mechanisms by which S1R modulates neurophysiology and implements neuroprotective functions in neurodegenerative diseases. These mechanisms are diverse due to the fact that S1R can bind to and modulate a large range of client proteins, including many ion channels in both ER and plasma membranes. We summarize the effect of S1R on its interaction partners and consider some of the cell type- and disease-specific aspects of these actions. Besides direct protein interactions in the endoplasmic reticulum, S1R is likely to function at the cellular/interorganellar level by altering the activity of several plasmalemmal ion channels through control of trafficking, which may help to reduce excitotoxicity. Moreover, S1R is situated in lipid rafts where it binds cholesterol and regulates lipid and protein trafficking and calcium flux at the mitochondrial-associated membrane (MAM) domain. This may have important implications for MAM stability and function in neurodegenerative diseases as well as cellular bioenergetics. We also summarize the structural and biochemical features of S1R proposed to underlie its activity. In conclusion, S1R is incredibly versatile in its ability to foster neuronal homeostasis in the context of several neurodegenerative disorders.

Indexed as

ALS (amyotrophic lateral sclerosis)Alzheimer’scalciumHuntington and Parkinson diseasesneuroprotectionsynapse

Identifiers

PMID31551669
PMCPMC6736580
OpenAlexW2964747275

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.